Mabion S.A. - Asset Resilience Ratio
Mabion S.A. (MAB) has an Asset Resilience Ratio of 0.03% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Mabion S.A. (MAB) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2018)
This chart shows how Mabion S.A.'s Asset Resilience Ratio has changed over time. See net assets of Mabion S.A. for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Mabion S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mabion S.A. (MAB) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł23.00K | 0.03% |
| Total Liquid Assets | zł23.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Mabion S.A. maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mabion S.A. Industry Peers by Asset Resilience Ratio
Compare Mabion S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Mabion S.A. (2012–2018)
The table below shows the annual Asset Resilience Ratio data for Mabion S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.07% | zł108.00K ≈ $29.72K |
zł144.72 Million ≈ $39.83 Million |
-4.62pp |
| 2014-12-31 | 4.69% | zł69.53 Million ≈ $19.14 Million |
zł1.48 Billion ≈ $407.64 Million |
-0.08pp |
| 2013-12-31 | 4.78% | zł36.06 Million ≈ $9.92 Million |
zł754.68 Million ≈ $207.70 Million |
-6.57pp |
| 2012-12-31 | 11.34% | zł449.85 Million ≈ $123.81 Million |
zł3.97 Billion ≈ $1.09 Billion |
-- |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development… Read more